Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

NEUROCRINE BIOSCIENCES, INC.

(NBIX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/24/2021 11/26/2021 11/29/2021 11/30/2021 12/01/2021 Date
87.86(c) 86.98(c) 84.74(c) 83.25(c) 80.79(c) Last
577 480 510 431 831 180 2 994 481 983 354 Volume
+0.90% -1.00% -2.58% -1.76% -2.95% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 1 141 M - -
Net income 2021 156 M - -
Net cash position 2021 991 M - -
P/E ratio 2021 50,8x
Yield 2021 -
Sales 2022 1 400 M - -
Net income 2022 308 M - -
Net cash position 2022 1 526 M - -
P/E ratio 2022 25,7x
Yield 2022 -
Capitalization 7 664 M 7 664 M -
EV / Sales 2021 5,85x
EV / Sales 2022 4,38x
Nbr of Employees 917
Free-Float 98,1%
More Financials
Company
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is focused on discovering, developing, and delivering treatments for people with neurological, endocrine and psychiatric disorders. Its portfolio includes treatments for tardive dyskinesia, ParkinsonÔÇÖs disease, endometriosis, uterine fibroids, and clinical programs in multiple therapeutic areas. The Company's product... 
Sector
Biotechnology & Medical Research
Calendar
11/30 | 10:55amPresentation
More about the company
Ratings of Neurocrine Biosciences, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about NEUROCRINE BIOSCIENCES, INC.
11/30Neurocrine Biosciences Names Jude Onyia Chief Scientific Officer
MT
11/30Neurocrine Biosciences Appoints Jude Onyia, Ph.D., as Chief Scientific Officer
PR
11/30Neurocrine Biosciences, Inc. Appoints Jude Onyia, Ph.D., as Chief Scientific Officer
CI
11/23Sosei Group Inks Licensing and Collaboration Deal for $100 Million Cash, Other Payments
MT
11/22Neurocrine Biosciences, Sosei Heptares Team Up to Develop Treatments for Schizophrenia,..
MT
11/22NEUROCRINE BIOSCIENCES : and Sosei Heptares Announce Collaboration to Develop Novel Muscar..
PU
11/22NEUROCRINE BIOSCIENCES INC : Entry into a Material Definitive Agreement (form 8-K)
AQ
11/22Neurocrine Biosciences and Sosei Heptares Announce Collaboration to Develop Novel Musca..
PR
11/22Neurocrine Biosciences, Inc. and Sosei Group Corporation Signs A Strategic Collaboratio..
CI
11/19BMO Capital Starts Neurocrine Biosciences at Underperform With $76 Price Target
MT
11/17WALL STREET STOCK EXCHANGE : The return of inflation fears
11/17ANALYST RECOMMENDATIONS : Diageo, Hyatt, Marks & Spencer, Sea Limited, Boeing, The Home De..
11/17JPMorgan Upgrades Neurocrine Biosciences to Overweight From Neutral; Price Target is $1..
MT
11/09Neurocrine Biosciences to Present at Upcoming Healthcare Conferences
PR
11/02Health Care Stocks Pare Gains Ahead of Close Tuesday
MT
More news
News in other languages on NEUROCRINE BIOSCIENCES, INC.
11/22Neurocrine Biosciences et Sosei Heptares s'associent pour développer des traitements co..
11/02Les actions du secteur de la santé réduisent leurs gains avant la clôture de mardi
11/02Les actions du secteur de la santé contribuent à la hausse des marchés plus larges mard..
11/01Neurocrine Biosciences réalise un bénéfice au troisième trimestre inférieur aux estimat..
11/01Earnings Flash (NBIX) NEUROCRINE BIOSCIENCES affiche un chiffre d'affaires de 296 milli..
More news
Analyst Recommendations on NEUROCRINE BIOSCIENCES, INC.
More recommendations
Chart NEUROCRINE BIOSCIENCES, INC.
Duration : Period :
Neurocrine Biosciences, Inc. Technical Analysis Chart | NBIX | US64125C1099 | MarketScreener
Technical analysis trends NEUROCRINE BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 80,79 $
Average target price 121,21 $
Spread / Average Target 50,0%
EPS Revisions
Managers and Directors
Kevin Charles Gorman Chief Executive Officer & Director
Matthew C. Abernethy Chief Financial Officer
William H. Rastetter Chairman
Dimitri E. Grigoriadis Chief Research Officer
Bill Wilson Vice President-Information Technology & Operations
Sector and Competitors
1st jan.Capi. (M$)
NEUROCRINE BIOSCIENCES, INC.-13.15%7 664
GILEAD SCIENCES, INC.18.31%86 465
BIONTECH SE310.30%80 784
WUXI APPTEC CO., LTD.30.33%67 780
REGENERON PHARMACEUTICALS31.76%65 932
VERTEX PHARMACEUTICALS-13.26%52 122